Allergic reactions to Pfizer, Moderna COVID-19 vaccines focus of new clinical trial
April 07, 2021 at 17:22
The National Institutes of Health (NIH) has launched a clinical trial to better understand allergic reactions related to the Moderna and Pfizer- BioNTech COVID-19 vaccines.
The trial, which will involve 3,400 adults, 60% of whom have a history of severe allergic reactions or a diagnosis of mast cell disorder, will also consider the biological mechanism behind the reactions to see if a genetic pattern or other factors can better predict who is at risk of a reaction.
The Centers for Disease Control and Prevention (CDC) first reported on the instances of anaphylaxis weeks after the initial rollout of the COVID-19 vaccines.
In rare cases, some recipients experienced adverse reactions such as severe allergic reactions within minutes of the vaccine being administered.
UK CORONAVIRUS VARIANT NOW 'MOST COMMON LINEAGE' IN US, WALENSKY SAYS"The public understandably has been concerned about reports of rare, severe allergic reactions to the Moderna and Pfizer-BioNTech COVID-19 vaccines," Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), said in a news release.
"The information gathered during this trial will help doctors advise people who are highly allergic or have a mast cell disorder about the risks and benefits of receiving these two vaccines.
However, for most people, the benefits of COVID-19 vaccination far outweigh the risks."
MOST CHILDREN WITH MIS-C EXPERIENCED ONLY MILD CORONAVIRUS SYMPTOMS PRIOR TO INFLAMMATORY ILLNESS: STUDYIn the trial, researchers will collect blood, urine and nasal swabs from participants before the jab, and blood and urine after.
The participants will also be monitored for at least 90 minutes after each injection.
Researchers will analyze the proportion of study participants in each group who experienced a systemic allergic reaction within 90 minutes of either dose.
"If a significant number of systemic allergic reactions to either or both vaccines occur during the trial, investigators will analyze these biological samples to examine possible mechanisms for the reactions and whether certain genetic patterns are associated with higher risk," the news release said.
CLICK HERE FOR COMPLETE CORONAVIRUS COVERAGEThe researchers expect to have results by late summer.